ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 473

Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis

Leena R Baghdadi1,2,3, Richard J Woodman2, E Michael Shanahan4 and Arduino A Mangoni3, 1Department of Family and Community Medicine, King Saud University, Riyadh, Saudi Arabia, 2Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia, 3Department of Clinical Pharmacology, Flinders University, Adelaide, Australia, 4Department of Rheumatology, Flinders University, Adelaide, Australia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, Cardiovascular disease, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Methotrexate (MTX) use has been associated with reduced cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Although MTX has anti-inflammatory effects, there is little evidence to support additional salutary effects on markers of cardiovascular risk such as blood pressure (BP) and arterial wave reflection (augmentation index, AIx), an indirect marker of arterial stiffness. Observational studies have suggested a lower systolic BP (SBP) in MTX users, approximately 3 mmHg, but it is unknown whether this is independent of anti-inflammatory effects. Thus, the purpose is to investigate associations between MTX, SBP and AIx in RA patients.

Methods: Using a cross-sectional study design, a total of 86 patients with RA (diagnosed using the 2010 American College of Rheumatology criteria) were recruited from rheumatology outpatient clinics at Flinders Medical Centre and Repatriation General Hospital, Adelaide, Australia. Participants were classified according to MTX exposure: MTX and non-MTX (defined as off MTX for >1 year or MTX naïve).

Results: There were 56 MTX (70% female; mean age 61 years) and 30 non-MTX patients (76% female; mean age 63 years). After adjusting for age, mean ±SD clinical SBP was significantly lower in MTX patients (124±1.9 mmHg, p<0.001) compared to non-MTX patients (131±2.9 mmHg, p<0.001). There were similar differences for central SBP 115 ±1.9 vs. 122 ±3 mmHg, p<0.001). MTX use was also associated with lower AIx (28%, 95% CI= 25.7, 29.9 vs. 31%, 95% CI= 27.5, 34.5, p< 0.001). Changes in the global inflammatory marker (ESR) and disease activity score (DAS28) and anti-CCP were not significantly associated with clinical SBP (p=0.80, 0.79 and 0.65) or AIx (p=0.86, 0.76 and 0.051), respectively. Changes in the short-term inflammatory marker CRP were associated with SBP (β=0.42±0.17, p=0.02), but not AIx (β=0.86±0.1, p=0.37). 

Conclusion: Our findings show that the use of MTX is associated with lower systolic blood pressure, which is associated with reduced inflammation. The lower arterial wave reflection in MTX patients was independent of changes in inflammation.


Disclosure: L. R. Baghdadi, None; R. J. Woodman, None; E. M. Shanahan, None; A. A. Mangoni, None.

To cite this abstract in AMA style:

Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/methotrexate-blood-pressure-and-arterial-wave-reflection-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-blood-pressure-and-arterial-wave-reflection-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology